Super Macrophages: New drugs that enhance killing of tuberculosis and other bacteria
Our group has developed the first inhibitors of the nitric oxide-regulating protein family known as SPSB. These inhibitors cause increased NO levels in macrophages and improve macrophage killing of bacteria including M. tuberculosis. We are currently developing a range of inhibitors that include cyclic peptides and small molecules. Lead compounds will be the first members of this exciting new class of antibiotics.
Enhanced research experiences
This project may be tailored to include any of the following: small molecule synthesis, peptide design and synthesis, computational modelling, chemical biology, NMR-based structure determination, X-ray crystallography, protein expression and purification, cell biology, microscopy and drug-polymer delivery systems. Research performed outside the medicinal chemistry theme may include cell biology (Sandra Nicholson, WEHI, Parkville), microscopy (Cameron Nowell, DDB) and animal models of infection (Monash & University of Technology, Sydney).